FIELD: medicine.
SUBSTANCE: method involves quantitatively estimating immature and mature cells belonging to myeloid hematosis differon with eosiniphils and basophils and their predecessor cells being additionally taken into account beginning from myeloblasts. Myeloid differon index MDI is defined as ratio of sum of neutrophil, eosiniphil and basophil myeloblasts, promyelocytes, myelocytes, metamyelocytes to sum of stab neutrophils and segmentonuclear neutrophils, eosiniphils and basophils. MDI being less than 0.55, inhibited myeloid differon activity is considered to be the case. MDI being greater than 0.60, increased myeloid differon activity is considered to be the case.
EFFECT: high accuracy and reliability of evaluation method.
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF RESTORING MYELOID TISSUE OF OLD LABORATORY ANIMALS AFTER INFLUENCE OF IONISING IRRADIATION | 2008 |
|
RU2394585C1 |
| METHOD FOR PREDICTION OF LEUKAEMIA DISEASE IN PEOPLE EXPOSED TO CHRONIC RADIATION EXPOSURE (EMBODIMENTS) | 2019 |
|
RU2713458C1 |
| METHOD OF PREPARING ORGANOSPECIFIC HOMEOPATHIC PREPARATIONS STIMULATING MYELOID AND LYMPHOID HEMOPOIESIS STEMS | 1995 |
|
RU2083213C1 |
| HEMOSTIMULANT AND PHARMACEUTICAL COMPOSITION AND METHOD FOR HEMOPOIESIS STIMULATION | 2011 |
|
RU2482869C1 |
| METHOD OF ESTIMATING CLINICAL EFFECTIVENESS IN CHRONIC MYELOID LEUKEMIA | 2012 |
|
RU2495430C1 |
| METHOD OF FORMING CONTROL GROUPS OF HEALTHY PEOPLE | 2022 |
|
RU2796890C1 |
| METHOD FOR DIFFERENTIAL DIAGNOSIS OF TOXEMIAS AND SEPTICEMIA CASES | 1991 |
|
RU2092839C1 |
| METHOD FOR PREDICTION OF CLINICAL EFFECTIVENESS IN CHRONIC MYELOID LEUKEMIA | 2012 |
|
RU2481583C1 |
| METHOD OF DIAGNOSING ONCOLOGICAL DISEASES OF THE BLOOD | 2022 |
|
RU2803281C1 |
| METHOD FOR ASSESSING HUMAN LEUKOGRAM ENTROPY | 2011 |
|
RU2466402C1 |
